Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Single-agent high-dose melphalan followed by peripheral blood stem cell (PBSC) in lymphoma patients: an effective, and well-tolerated conditioning regimen

Bone Marrow Transplantation volume 33, pages 1067–1068 (2004)Cite this article

High-dose chemotherapy (HDCT) and autologous bone marrow (ABMT) or peripheral blood stem cell transplantation (PBSCT) is the treatment of choice for relapsed or refractory lymphoma patients.1,2 Although the optimal HDCT regimen is unknown, combinations with non-cross-resistant agents are commonly used.3,4

Data about the efficacy of single-agent high-dose melphalan (HD-PAM) in lymphoma patients are few.5,6,7 From July 2000, in our Institution, we investigated the efficacy of HD-PAM in poor-prognosis lymphoma patients.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Linch DC, Winfield D, Goldstone AH et al. Dose intensification with autologous bone marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet 1993; 341: 1051–1054.

    Article  CAS  Google Scholar 

  2. Philip T, Guglielmi C, Hagenbeek A et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333: 1540–1545.

    Article  CAS  Google Scholar 

  3. Jagannath S, Dicke KA, Armitage JO et al. High-dose cyclophosphamide, carmustine, and etoposide and autologous bone marrow transplantation for relapsed Hodgkin's disease. Ann Intern Med 1986; 104: 163–168.

    Article  CAS  Google Scholar 

  4. Chopra R, McMillan AK, Linch DC et al. The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. A single-center eight-year study of 155 patients. Blood 1993; 81: 1137–1145.

    CAS  Google Scholar 

  5. Russell JA, Selby PJ, Ruether BA et al. Treatment of advanced Hodgkin's disease with high dose melphalan and autologous bone marrow transplantation. Bone Marrow Transplant 1989; 4: 425–429.

    CAS  PubMed  Google Scholar 

  6. Stewart DA, Guo D, Sutherland JA et al. Single-agent high-dose melphalan salvage therapy for Hodgkin's disease: cost, safety, and long-term efficacy. Ann Oncol 1997; 8: 1277–1279.

    Article  CAS  Google Scholar 

  7. Selby PJ, Mbidde EK, Maitland J, McElwain TJ . High-dose melphalan and autologous bone marrow transplant as treatment for refractory Hodgkin's disease. J Clin Oncol 1986; 4: 612.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology and Hematology, Istituto Clinico Humanitas, Rozzano Milano, Italy

    M Magagnoli, L Castagna, S Bramanti, M Balzarotti & A Santoro

Authors
  1. M Magagnoli
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L Castagna
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S Bramanti
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M Balzarotti
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A Santoro
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Magagnoli, M., Castagna, L., Bramanti, S. et al. Single-agent high-dose melphalan followed by peripheral blood stem cell (PBSC) in lymphoma patients: an effective, and well-tolerated conditioning regimen. Bone Marrow Transplant 33, 1067–1068 (2004). https://doi.org/10.1038/sj.bmt.1704492

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1704492

This article is cited by

Search

Advanced search

Quick links